Beta

Promis neurosciences, inc.PMN.US Overview

US StockHealthcare
(No presentation for PMN)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

PMN AI Insights

PMN Overall Performance

PMN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

PMN Recent Performance

-2.25%

Promis neurosciences, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

PMN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check PMN's Trend

PMN Key Information

PMN Valuation Metrics

PMN Profile

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Price of PMN

PMN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

PMN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-30.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4016.22
PB Ratio
17.28
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-30.38
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
4016.22
PB Ratio
17.28
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is PMN's latest earnings report released?

    The most recent financial report for Promis neurosciences, inc. (PMN) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PMN's short-term business performance and financial health. For the latest updates on PMN's earnings releases, visit this page regularly.

  • How much cash does PMN have?

    At the end of the period, Promis neurosciences, inc. (PMN) held Total Cash and Cash Equivalents of 6.12M, accounting for 0.67 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is PMN's EPS continuing to grow?

    According to the past four quarterly reports, Promis neurosciences, inc. (PMN)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.11. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of PMN?

    Promis neurosciences, inc. (PMN)'s Free Cash Flow (FCF) for the period is -9.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 6.5% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of PMN?

    The latest valuation data shows Promis neurosciences, inc. (PMN) has a Price-To-Earnings (PE) ratio of -3.58 and a Price/Earnings-To-Growth (PEG) ratio of 0.02. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.